

Annalisa Ruggeri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5870459/publications.pdf>

Version: 2024-02-01

264
papers

8,574
citations

47006

47
h-index

56724

83
g-index

266
all docs

266
docs citations

266
times ranked

7947
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. <i>Lancet Oncology</i> , The, 2010, 11, 653-660.	10.7	532
2	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	1.4	340
3	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. <i>Blood</i> , 2014, 123, 133-140.	1.4	239
4	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , 2020, 217, 108509.	3.2	236
5	Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 95-97.	0.1	235
6	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWPâ€EBMT analysis on patients with AML in remission. <i>Bone Marrow Transplantation</i> , 2016, 51, 610-611.	2.4	212
7	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
8	Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. <i>Blood</i> , 2013, 122, 1072-1078.	1.4	210
9	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	7.2	199
10	Effect of donorâ€recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1214-1221.	10.7	192
11	Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1375-1382.	2.0	188
12	Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. <i>Blood</i> , 2013, 121, 3981-3987.	1.4	183
13	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , 2018, 124, 1428-1437.	4.1	131
14	Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. <i>Journal of Hematology and Oncology</i> , 2018, 11, 40.	17.0	130
15	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
16	Milestones in umbilical cord blood transplantation. <i>British Journal of Haematology</i> , 2011, 154, 441-447.	2.5	122
17	Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. <i>Haematologica</i> , 2013, 98, 1154-1160.	3.5	117
18	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	1.4	110

#	ARTICLE	IF	CITATIONS
19	Post-transplant cyclophosphamide <i>versus</i> anti-thymocyte globulin as graft- <i>versus</i> -host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	3.5	109
20	Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 78-85.	2.0	100
21	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 2867-2874.	4.1	100
22	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
23	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	7.2	95
24	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. <i>Haematologica</i> , 2019, 104, 1682-1688.	3.5	91
25	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
26	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 1317-1328.	3.5	84
27	Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1890-1896.	2.0	82
28	Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 816-822.	2.0	80
29	Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. <i>Blood</i> , 2013, 122, 2135-2141.	1.4	79
30	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	5.2	76
31	Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 822-830.	1.7	72
32	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	4.6	72
33	Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. <i>Transplant Infectious Disease</i> , 2011, 13, 456-465.	1.7	70
34	Family-directed umbilical cord blood banking. <i>Haematologica</i> , 2011, 96, 1700-1707.	3.5	69
35	New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013, 121, 1059-1064.	1.4	69
36	Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. <i>Blood</i> , 2015, 126, 1027-1032.	1.4	69

#	ARTICLE	IF	CITATIONS
37	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	17.0	68
38	Unrelated Cord Blood Transplantation. <i>Transplantation</i> , 2013, 95, 1284-1291.	1.0	66
39	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	3.5	64
40	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 113.	17.0	60
41	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1013-1021.	2.0	59
42	Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. <i>Haematologica</i> , 2014, 99, 370-377.	3.5	55
43	Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 223-229.	1.7	54
44	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	2.4	54
45	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
46	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53
47	Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP EBMT analysis. <i>Leukemia</i> , 2012, 26, 2455-2461.	7.2	51
48	Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2018, 11, 55.	17.0	51
49	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
50	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	3.5	48
51	Pediatric related and unrelated cord blood transplantation for malignant diseases. <i>Bone Marrow Transplantation</i> , 2009, 44, 653-659.	2.4	47
52	Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. <i>Bone Marrow Transplantation</i> , 2015, 50, 45-50.	2.4	47
53	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. <i>Haematologica</i> , 2019, 104, e543-e546.	3.5	47
54	Double cord blood transplantation in patients with high risk bone marrow failure syndromes. <i>British Journal of Haematology</i> , 2008, 143, 404-408.	2.5	46

#	ARTICLE	IF	CITATIONS
55	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <i>Blood Advances</i> , 2018, 2, 49-60.	5.2	45
56	Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Soci�t� Fran�saise de Greffe de Moelle-Therapie Cellulaire collaborative study. <i>Bone Marrow Transplantation</i> , 2013, 48, 253-256.	2.4	44
57	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <i>Blood</i> , 2018, 132, 750-754.	1.4	44
58	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	17.0	44
59	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017, 1, 669-680.	5.2	43
60	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1407-1415.	2.0	42
61	Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. <i>Haematologica</i> , 2014, 99, 535-540.	3.5	41
62	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	17.0	41
63	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
64	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	4.1	40
65	Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 207-216.	1.7	37
66	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	7.2	36
67	Decreased in-hospital mortality in patients with COVID-19 pneumonia. <i>Pathogens and Global Health</i> , 2020, 114, 281-282.	2.3	36
68	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood�a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	17.0	35
69	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 89.	17.0	35
70	Development of adaptive immune effector therapies in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1740-1750.	1.2	35
71	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. <i>Expert Review of Hematology</i> , 2016, 9, 297-314.	2.2	34
72	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1499-1510.	2.4	34

#	ARTICLE	IF	CITATIONS
73	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	1.6	34
74	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <i>Clinical Cancer Research</i> , 2018, 24, 2794-2803.	7.0	32
75	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	32
76	Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. <i>Bone Marrow Transplantation</i> , 2014, 49, 24-29.	2.4	31
77	Impact of <scp>HLA</scp> in cord blood transplantation outcomes. <i>Hla</i> , 2016, 87, 413-421.	0.6	31
78	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. <i>Haematologica</i> , 2017, 102, 1112-1119.	3.5	30
79	Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 445-453.	2.0	29
80	Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 592-599.	2.4	29
81	Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of. <i>British Journal of Haematology</i> , 2014, 166, 749-757.	2.5	28
82	Killer Cell Immunoglobulin-Like Receptorâ€“Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1284-1289.	2.0	28
83	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
84	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1471-1475.	2.0	28
85	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
86	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	17.0	27
87	Occurrence of graftâ€“versusâ€“host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , 2018, 283, 178-189.	6.0	26
88	Postâ€“transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLAâ€“identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 209-218.	4.1	26
89	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , the, 2021, 8, e205-e215.	4.6	26
90	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1350-1358.	2.0	25

#	ARTICLE	IF	CITATIONS
91	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1987-1994.	2.4	25
92	Optimizing cord blood selection. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 522-531.	2.5	25
93	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
94	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 887-894.	2.4	23
95	Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1574-1577.	2.4	23
96	Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 283-290.	1.7	22
97	Alternative donors: cord blood for adults. <i>Seminars in Hematology</i> , 2016, 53, 65-73.	3.4	22
98	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 799-805.	2.0	22
99	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018, 93, 769-777.	4.1	22
100	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
101	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 424.e1-424.e9.	1.2	22
102	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017, 8, 112972-112979.	1.8	22
103	Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. <i>Leukemia</i> , 2017, 31, 1408-1414.	7.2	21
104	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTWIP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 128.	17.0	21
105	Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. <i>British Journal of Haematology</i> , 2015, 169, 103-110.	2.5	20
106	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1939-1948.	2.0	19
107	Myelodysplastic syndromes in children. <i>Current Opinion in Oncology</i> , 2018, 30, 402-408.	2.4	19
108	CD34 -selected stem cell "boost" for poor graft function after allogeneic hematopoietic stem cell transplantation. <i>Current Research in Translational Medicine</i> , 2019, 67, 112-114.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2019, 187, e64-e68.	2.5	18
110	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 46.	6.2	18
111	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. <i>Lancet Haematology</i> , 2020, 7, e902-e911.	4.6	18
112	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. <i>Leukemia</i> , 2021, 35, 585-594.	7.2	18
113	Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1997-2002.	2.0	17
114	Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis. <i>Transfusion</i> , 2016, 56, 2021-2029.	1.6	17
115	Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1295-1303.	2.4	17
116	Impact of cyclosporine A concentration on acute graft-versus-host disease incidence after haploidentical hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 10-17.	2.2	17
117	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. <i>Cancer</i> , 2019, 125, 1499-1506.	4.1	17
118	Second allogeneic hematopoietic cell transplantation using HLA-matched unrelated versus cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
119	Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 1120-1127.	3.5	16
120	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. <i>Haematologica</i> , 2018, 103, e103-e105.	3.5	16
121	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 763-772.	2.4	16
122	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	2.4	16
123	The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. <i>Bone Marrow Transplantation</i> , 2020, 55, 1946-1954.	2.4	14
124	Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study. <i>Bone Marrow Transplantation</i> , 2018, 53, 231-233.	2.4	13
125	Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 713-718.	2.4	13
126	Iron Burden and Liver Fibrosis Decrease During a Long-Term Phlebotomy Program and Iron Chelating Treatment After Bone Marrow Transplantation. <i>Hemoglobin</i> , 2006, 30, 131-137.	0.8	12

#	ARTICLE	IF	CITATIONS
127	A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2019, 185, 918-924.	2.5	12
128	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	4.1	12
129	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 76.	17.0	12
130	Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2021, 9, 59.	0.8	12
131	Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Medicinal Chemistry</i> , 2018, 25, 4535-4544.	2.4	12
132	Use of the HLA-B leader to optimize cord blood transplantation. <i>Haematologica</i> , 2021, 106, 3107-3114.	3.5	12
133	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societ� Fran�aise de Greffe de Moelle et Therapie	2.0	11
134	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1657-1663.	2.0	11
135	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2120-2120.	1.4	11
136	Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Blood</i> , 2016, 128, 2671-2671.	1.4	11
137	Impact of the Addition of Antithymocyte Globulin to Post-transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 587.e1-587.e7.	1.2	11
138	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. <i>Bone Marrow Transplantation</i> , 2018, 53, 1201-1205.	2.4	10
139	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
140	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2019, 184, 397-404.	2.5	10
141	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.4	10
142	Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease. <i>Frontiers in Immunology</i> , 2020, 11, 2041.	4.8	10
143	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (<sc>ALWP</sc>) of the <sc>European group for blood and marrow transplantation (EBMT)</sc>. <i>American Journal of Hematology</i> , 2021, 96, 40-50.	4.1	10
144	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10

#	ARTICLE	IF	CITATIONS
145	Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. <i>Blood Advances</i> , 2020, 4, 6327-6335.	5.2	10
146	Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1717-1720.	2.0	9
147	Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. <i>Haematologica</i> , 2017, 102, e271-e274.	3.5	9
148	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <i>British Journal of Haematology</i> , 2017, 179, 790-801.	2.5	9
149	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriersâ€”On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9
150	Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 249-261.	0.7	9
151	Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks. <i>Haematologica</i> , 2017, 102, 976-983.	3.5	8
152	Tâ€œcellâ€ depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2018, 124, 2142-2150.	4.1	8
153	Cord blood transplantation for bone marrow failure syndromes: state of art. <i>Stem Cell Investigation</i> , 2019, 6, 39-39.	3.0	8
154	Administration of BPX-501 Cells Following AÎ² T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. <i>Blood</i> , 2018, 132, 307-307.	1.4	8
155	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , 2010, 116, 910-910.	1.4	8
156	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	2.4	8
157	Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. <i>Blood</i> , 2017, 129, 525-532.	1.4	7
158	Current practices for screening, consent and care of related donors in France: Haematopoietic stem cell transplantation coordinator nursesâ€™ perceptions. <i>European Journal of Cancer Care</i> , 2017, 26, e12612.	1.5	7
159	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2438-2446.	2.0	7
160	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , 2016, 128, 1165-1165.	1.4	7
161	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 710.e1-710.e10.	1.2	7
162	<sc>UK</sc> experience of unrelated cord blood transplantation in paediatric patients. <i>British Journal of Haematology</i> , 2016, 172, 482-486.	2.5	6

#	ARTICLE	IF	CITATIONS
163	Unrelated cord blood transplantation for childhood acute myelogenous leukemia: The influence of cytogenetic risk group stratification. <i>Leukemia</i> , 2016, 30, 1180-1183.	7.2	6
164	Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2021, 56, 2497-2509.	2.4	6
165	Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen. <i>Blood</i> , 2012, 120, 232-232.	1.4	6
166	Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 672-672.	1.4	6
167	Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2022, 57, 125-127.	2.4	6
168	Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia. <i>Stem Cells Translational Medicine</i> , 2022, 11, 407-414.	3.3	6
169	Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 96-102.	2.0	5
170	HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2034-2039.	2.0	5
171	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	2.4	5
172	Long-term treatment with deferiprone in a L1 veteran. <i>European Journal of Haematology</i> , 2005, 74, 523-525.	2.2	4
173	Impact of Myeloablative and Reduced Intensity Conditioning on Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S127.	2.0	4
174	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019, 285, 446-454.	6.0	4
175	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1842-1849.	2.4	4
176	Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant Disorders. A Eurocord-EBMT Analysis. <i>Blood</i> , 2010, 116, 223-223.	1.4	4
177	Hematopoietic Stem Cell Transplantation from HLA Identical Sibling For Sickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR. <i>Blood</i> , 2015, 126, 541-541.	1.4	4
178	Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial. <i>Blood</i> , 2016, 128, 65-65.	1.4	4
179	Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 46.e1-46.e7.	1.2	4
180	Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients. <i>EJHaem</i> , 2020, 1, 208-218.	1.0	3

#	ARTICLE	IF	CITATIONS
181	Trend towards reduction in COVID-19 in-hospital mortality. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100059.	5.6	3
182	Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT. <i>Blood</i> , 2013, 122, 2156-2156.	1.4	3
183	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	1.4	3
184	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	2.5	3
185	Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1729-1735.	2.0	2
186	Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. <i>Current Research in Translational Medicine</i> , 2019, 67, 76-78.	1.8	2
187	Impact Of Rabbit Anti-Thymocyte Globulin-Containing Reduced-Intensity Conditioning Regimens On Outcomes Of Adults Undergoing Unrelated Cord Blood Transplantation For Hematological Malignancies. <i>Blood</i> , 2013, 122, 412-412.	1.4	2
188	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. <i>Blood</i> , 2014, 124, 1215-1215.	1.4	2
189	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. <i>Blood</i> , 2014, 124, 187-187.	1.4	2
190	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 399-399.	1.4	2
191	Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4624-4624.	1.4	2
192	Outcome Of Unrelated Umbilical Cord Blood Transplantation For Children With Osteopetrosis: An Eurocord and Inborn Errors Working Party (IEWP)-EBMT Study. <i>Blood</i> , 2013, 122, 2100-2100.	1.4	2
193	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	1.4	2
194	An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. <i>Cytotherapy</i> , 2022, 24, 385-392.	0.7	2
195	Relationships Between Connective Tissue Proteoglycans and Fibrous Proteins, as Shown by Electron Microscopy. <i>Upsala Journal of Medical Sciences</i> , 1977, 82, 74-74.	0.9	1
196	Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. <i>British Journal of Haematology</i> , 2016, 172, 478-481.	2.5	1
197	Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. <i>Bone Marrow Transplantation</i> , 2018, 53, 417-421.	2.4	1
198	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	2.4	1

#	ARTICLE	IF	CITATIONS
199	Impact of the human leucocyte antigen (HLA) ð leader peptide dimorphism and HLA ð expression on outcomes of stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2021, 195, e128-e131.	2.5	1
200	Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia. <i>Blood</i> , 2018, 132, 2169-2169.	1.4	1
201	Outcomes of Unrelated Cord Blood Transplantation for Non-Malignant Diseases in Children Are Not Associated with KIR-Ligand Matching Between Donor and Recipient: a Study On Behalf of Eurocord.. <i>Blood</i> , 2009, 114, 2301-2301.	1.4	1
202	Impact of Minimal Residual Disease at Unrelated Cord Blood Transplantation In Children with Acute Lymphoblastic Leukemia In Remission: a Study on Behalf of Eurocord-EBMT and EBMT-PDWP. <i>Blood</i> , 2010, 116, 532-532.	1.4	1
203	Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3111-3111.	1.4	1
204	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. <i>Blood</i> , 2015, 126, 3214-3214.	1.4	1
205	Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord. <i>Blood</i> , 2013, 122, 3394-3394.	1.4	1
206	Is There Any Effect of Killer Cell Immunoglobulin-like Receptor (KIR) on Outcomes after Single Unrelated Cord Blood Transplantation?. <i>Blood</i> , 2014, 124, 48-48.	1.4	1
207	Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 153-153.	1.4	1
208	Administration of BPX-501 Cells Following γ T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia. <i>Blood</i> , 2018, 132, 4654-4654.	1.4	1
209	Extracorporeal Photopheresis for First Line Treatment of Acute Graft Versus Host Disease. <i>Blood</i> , 2018, 132, 2114-2114.	1.4	1
210	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	2.4	1
211	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 0, ...	2.4	1
212	P156 Allogeneic stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia (sAML): results from a single centre experience. <i>Leukemia Research</i> , 2007, 31, S125-S126.	0.8	0
213	Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S127-S128.	2.0	0
214	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S126.	2.0	0
215	Outcomes of Allogeneic Cord Blood Transplantation for Leukodystrophies; A Joint Study of Eurocord and "Inborn Errors WP-EBMT". <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S86-S87.	2.0	0
216	New strategies of allogeneic hematopoietic stem cell transplantation with the use of haploidentical donors. <i>Hematologie</i> , 2016, 22, 98-110.	0.0	0

#	ARTICLE	IF	CITATIONS
217	Umbilical Cord Blood Transplantation for Patients With Acquired and Inherited Bone Marrow Failure Syndromes on Behalf of Eurocord. , 2017, , 111-119.		0
218	Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord. Biology of Blood and Marrow Transplantation, 2018, 24, S405.	2.0	0
219	Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord. Biology of Blood and Marrow Transplantation, 2018, 24, S406.	2.0	0
220	Sirolimus-based graft-versus-host disease prophylaxis. Lancet Haematology,the, 2019, 6, e387-e388.	4.6	0
221	Unmanipulated haploidentical transplantation for adult patients with hematological malignancies. HemaSphere, 2019, 3, 170-172.	2.7	0
222	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. Current Research in Translational Medicine, 2021, 69, 103313.	1.8	0
223	Is There an Impact of HLA Mismatch Direction on Outcomes After Umbilical Cord Blood Transplantation?. Blood, 2011, 118, 835-835.	1.4	0
224	Determining Late Engraftment Following Single Cord, Unrelated Transplantation: An Analysis of the Eurocord Registry. Blood, 2011, 118, 650-650.	1.4	0
225	Cost-Effectiveness of Double-Unit Cord Blood Transplantation Versus Single-Unit Cord Blood Transplantation in Adult Patients with Acute Leukaemia in France- On Behalf of SFGM-TC, Eurocord, ALWP-EBMT. Blood, 2011, 118, 3130-3130.	1.4	0
226	Influence of Cytogenetic, Molecular Abnormalities and Other Risk Factors on the Outcomes of Children with Acute Myelogenous Leukemia Given An Unrelated Cord Blood Transplantation. A Survey on Behalf of Eurocord, ALWP and PDWP of EBMT. Blood, 2011, 118, 834-834.	1.4	0
227	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. Blood, 2011, 118, 836-836.	1.4	0
228	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. Blood, 2012, 120, 3083-3083.	1.4	0
229	Unrelated Umbilical Cord Blood Transplantation: Characteristics and Outcomes In Older Patients With Hematological Malignancies In Europe and United States: A Eurocord/European Group For Blood and Marrow Transplantation (EBMT) and Center For International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2013, 122, 3339-3339.	1.4	0
230	Unrelated Cord Blood Transplantation For Infant Acute Leukemia Diagnosed Within 1 Year Of Age: Outcomes and Risk Factor Analysis On Behalf Of Eurocord and PDWP-EBMT. Blood, 2013, 122, 160-160.	1.4	0
231	Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT). Blood, 2013, 122, 3334-3334.	1.4	0
232	Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes. Blood, 2013, 122, 302-302.	1.4	0
233	Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and Inborn Errors WP-EBMT. Blood, 2013, 122, 2101-2101.	1.4	0
234	Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. Blood, 2014, 124, 2581-2581.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. <i>Blood</i> , 2014, 124, 2570-2570.	1.4	0
236	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	1.4	0
237	Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study. <i>Blood</i> , 2015, 126, 3203-3203.	1.4	0
238	Extracorporeal Photopheresis (ECP) for Acute Graft-Versus Host Disease (GvHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). <i>Blood</i> , 2015, 126, 5466-5466.	1.4	0
239	Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission. <i>Blood</i> , 2015, 126, 4384-4384.	1.4	0
240	Impact of CTLA4 Genotype and Other Immune Response Gene Polymorphisms on Outcomes after Umbilical Cord Blood Transplantation - a Eurocord, CBC-Ctiwb-EBMT, Netcord and FMRP-USP Study. <i>Blood</i> , 2015, 126, 400-400.	1.4	0
241	The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 3110-3110.	1.4	0
242	Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. <i>Blood</i> , 2016, 128, 3484-3484.	1.4	0
243	Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3428-3428.	1.4	0
244	Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT. <i>Blood</i> , 2016, 128, 4643-4643.	1.4	0
245	Revisiting Graft-Versus-Leukemia Effects after Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia : A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 2244-2244.	1.4	0
246	How to Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation: A Survey from the EBMT- Cellular Therapy & Immunobiology Working Party. <i>Blood</i> , 2016, 128, 4581-4581.	1.4	0
247	Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT. <i>Blood</i> , 2016, 128, 3488-3488.	1.4	0
248	CD34+ Selected Cells "Boost" for Poor Graft Function Post Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2300-2300.	1.4	0
249	Historical Perspective and Current Trends of Umbilical Cord Blood Transplantation. , 2017, , 1-12.		0
250	Stem Cell Source. , 2018, , 129-139.		0
251	UCB HCT in FLT3+ AML. <i>Oncotarget</i> , 2017, 8, 81733-81734.	1.8	0
252	Related-donors care: coordinatoor nursesâ€™ point of view. <i>Hematologie</i> , 2017, 23, 391-396.	0.0	0

#	ARTICLE	IF	CITATIONS
253	Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 661-661.	1.4	0
254	Achievement of High Concentration of Cyclosporine-a Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Graft. <i>Blood</i> , 2018, 132, 4565-4565.	1.4	0
255	A Polymorphism in Toll-like Receptor 2 Gene Is Associated with Occurrence of Bacterial Infections in Sickle Cell Disease Patients. <i>Blood</i> , 2018, 132, 3652-3652.	1.4	0
256	Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT. <i>Blood</i> , 2018, 132, 3369-3369.	1.4	0
257	Hematopoietic Recovery and Transfusion Needs after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2018, 132, 2109-2109.	1.4	0
258	Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmwp-EBMT. <i>Blood</i> , 2018, 132, 3475-3475.	1.4	0
259	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 1016-1016.	1.4	0
260	A Delayed Innate T Cell Reconstitution Is Associated with Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation Using Anti-Thymoglobulin and High-Dose Post-Transplant Cyclophosphamide. <i>Blood</i> , 2018, 132, 3398-3398.	1.4	0
261	The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT. <i>Blood</i> , 2018, 132, 3462-3462.	1.4	0
262	Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry. <i>Blood</i> , 2018, 132, 2106-2106.	1.4	0
263	The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2018, 132, 4639-4639.	1.4	0
264	Review of Unrelated Donor Cord Blood Transplantation in Children over the Past 3 Decades. <i>Blood</i> , 2021, 138, 2903-2903.	1.4	0